Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

GHRP-2 vs Hexarelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

This combination is flagged

Two GHRPs in the same regimen: Moderate risk per peptide research literature. Ghrelin receptor (GHS-R1a) saturation + accelerated desensitization; may blunt long-term GH response.

Data-derived verdict

GHRP-2 and Hexarelin share the ghrp / gh-secretagogue classes and carry roughly equivalent evidence (Japan-Approved Diagnostic / Phase 2 (not approved)). On the catalogued data layer Hexarelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Hexarelin's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

GHRP-2

Japan-Approved Diagnostic

Hexarelin

Phase 2 (not approved)

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: cortisol. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

GHRP-2 Hexarelin
Class GHRP; ghrelin receptor agonist GHRP; potent ghrelin receptor agonist
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism GHS-R1a agonist; strong GH release GHS-R1a agonist; more potent GH release than other GHRPs
Route SC / Intranasal SC / Intranasal
Half-life ~15-30 min ~1 hr
Dosage (research) 100-300 mcg SC 1-3x daily 100-200 mcg SC 1-2x daily (short cycles)
Evidence tier Japan-Approved Diagnostic Phase 2 (not approved)
Research depth 148 indexed (PubMed 139 · CT 0 · EPMC 9) 158 indexed (PubMed 141 · CT 0 · EPMC 17)
Availability Research Research Chemical
Reported risks Cortisol/prolactin increase; hunger; water retention Cortisol/prolactin elevation; pituitary desensitization

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick GHRP-2 or Hexarelin?

GHRP-2 and Hexarelin share the ghrp / gh-secretagogue classes and carry roughly equivalent evidence (Japan-Approved Diagnostic / Phase 2 (not approved)). On the catalogued data layer Hexarelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Hexarelin's evidence base is currently denser.

What is the difference between GHRP-2 and Hexarelin?

GHRP-2 is classed as GHRP; ghrelin receptor agonist; Hexarelin is classed as GHRP; potent ghrelin receptor agonist. Reported mechanism: GHRP-2, GHS-R1a agonist; strong GH release; Hexarelin, GHS-R1a agonist; more potent GH release than other GHRPs. Reported half-life: GHRP-2, ~15-30 min; Hexarelin, ~1 hr. Routes in published studies: GHRP-2, SC / Intranasal; Hexarelin, SC / Intranasal.

Which has stronger evidence, GHRP-2 or Hexarelin?

Hexarelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHRP-2 is graded Japan-Approved Diagnostic, with 1 cited source on its reference page and 148 indexed studies. Hexarelin is graded Phase 2 (not approved), with 4 cited sources on its reference page and 158 indexed studies.

Which is more accessible, GHRP-2 or Hexarelin?

Neither GHRP-2 nor Hexarelin is an FDA-approved drug. Catalog status: GHRP-2, Research; Hexarelin, Research Chemical. FDA lists GHRP-2 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).

Are GHRP-2 and Hexarelin ever combined?

GHRP-2 and Hexarelin appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two GHRPs in the same regimen, moderate risk.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…